

ESCEO-Amgen Osteoporosis Fellowship Award 2011

Recipient's Obligations.

- (a) Reports to AMGEN. For each six (6) month period Recipient will provide Amgen with a detailed written report summarizing Recipient's use of the Donation during the preceding six (6) months. Such report must detail; (i) the research performed pursuant to the Fellowship and (ii) the results of such research. The manuscript must be of a standard that is suitable for submission to a reputable peer reviewed journal.
- (b) All publications, during a period of three years following the allocation of the grant, should acknowledge the support obtained through the ESCEO-AMGEN fellowship.
- (c) Any manuscript, prepared during a twelve-month period after the allocation of the grant, will be submitted to Amgen for review and comment at least 60 days prior to submission of a publication. All reasonable comments by Amgen in the relation to the correction of factual errors will be incorporated into the publication.
- (d) Use of Logos. The Donation is made on the condition that Amgen's support shall be clearly acknowledged, this may be achieved through references in documentation related to the Supported Activity as follows: "Supported by Amgen" and/or the Amgen logo appearing on the Recipient's website with a link to www.amgen.be through the display of the Amgen logo. Except as provided herein, Recipient undertakes not to use Amgen name nor any trademark or other distinctive signs belonging to the Amgen group in any statements or public announcements without Amgen's prior written consent. Amgen shall have the right to use, copy and publish the name, trademark, or logo of the Recipient in order to comply with transparency reporting requirements to which it may be subject.
- (e) Publication Rights. In the event that the report prepared contains information suitable for publication ESCEO will include in the fellowship regulations that it is a condition of the Fellowships that any manuscript will be submitted to Amgen for review and comment at least sixty (60) days prior to submission for publication. All reasonable comments made by Amgen in relation to the correction of factual errors will be incorporated into the publication.